Piper Sandler Reiterates Overweight on Beta Bionics, Raises Price Target to $24
Benzinga Newsdesk 4 days ago
Analyst RatingsNewsReiterationPrice Target
Piper Sandler analyst Matt O'Brien reiterates Beta Bionics (NASDAQ:BBNX) with a Overweight and raises the price target from $20 to $24.
Piper Sandler analyst Matt O'Brien reiterates Beta Bionics (NASDAQ:BBNX) with a Overweight and raises the price target from $20 to $24.